Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

S215. Fronto-temporal cerebral blood flow and cognitive functioning in patients with first episode psychoses treated with aripiprazole: preliminary findings (CROSBI ID 708798)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa

Peitl, Vjekoslav ; Silić, Ante ; Ostojić, Draženka ; Aukst Margetić, Branka ; Šiško Markoš, Ines ; Bogović Dijaković, Anamarija ; Rendulić, Ana ; Karlović, Dalibor S215. Fronto-temporal cerebral blood flow and cognitive functioning in patients with first episode psychoses treated with aripiprazole: preliminary findings // Schizophrenia bulletin. 2020. str. S120-S120 doi: 10.1093/schbul/sbaa031.281

Podaci o odgovornosti

Peitl, Vjekoslav ; Silić, Ante ; Ostojić, Draženka ; Aukst Margetić, Branka ; Šiško Markoš, Ines ; Bogović Dijaković, Anamarija ; Rendulić, Ana ; Karlović, Dalibor

engleski

S215. Fronto-temporal cerebral blood flow and cognitive functioning in patients with first episode psychoses treated with aripiprazole: preliminary findings

Abstract Background Cognitive dysfunctions have long been observed in patients with schizophrenia, while cognitive symptoms are receiving a lot of attention due to the fact they can be considered core symptoms of schizophrenia. Cerebral blood flow has been by some researchers associated with cognitive functioning, or at least some aspects of cognitive functions. Because of its distinctive psychopharmacologic properties, aripiprazole is deemed a substantially different antipsychotic compared to the majority of the available compounds. It has been hypothesised that due to this fact it could have beneficial effects especially on cognition in schizophrenia. In line with that thought, the objective of this study was to investigate whether use of an atypical antipsychotic aripiprazole has beneficial effects on cerebral blood flow and cognitive functioning in patients with a first episode of schizophrenia during a three month treatment. Methods Forty patients were included in the ongoing study. At baseline and at three month follow up schizophrenia symptomatology was assessed by PANSS, cognitive functions by 5-KOG screening instrument for cognition in psychiatry, while cerebral blood flow was assessed by 99mTc-D, L- hexamethylene-propyleneamine oxime (99mTc-HMPAO) using a SPECT technique. Results After three months of treatment, we observed a significant improvement of schizophrenia symptoms and cognitive functions, measured by PANSS and 5- KOG, with all of the five subscales of the latter and its total score being significantly higher than at baseline (p<0.05). Similarly, cerebral blood-flow measured by SPECT improved at three months follow up compared to baseline. Discussion Use of aripiprazole in first episode patients with schizophrenia is associated with increased fronto- temporal cerebral blood flow and improvement of schizophrenia symptomatology, including cognition indices. Although we cannot confirm it directly, it is possible that improved fronto-temporal cerebral blood flow led to the improvement in cognition indices.

cognitive functions ; patient ; schizophrenia symptoms ; aripiprazole

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

S120-S120.

2020.

nije evidentirano

objavljeno

10.1093/schbul/sbaa031.281

Podaci o matičnoj publikaciji

Schizophrenia bulletin

Firenza : München:

0586-7614

Podaci o skupu

Schizophrenia International Research Society

poster

01.01.2020-01.01.2020

Firenca, Italija

Povezanost rada

Kliničke medicinske znanosti

Poveznice